On June 23, the Advisory Committee on Immunization Practices (ACIP) at the CDC met to discuss ongoing reports of myocarditis in young people, particul

Weighing myocarditis cases, ACIP failed to balance the harms vs benefits of 2nd doses

submited by
Style Pass
2021-06-25 19:00:05

On June 23, the Advisory Committee on Immunization Practices (ACIP) at the CDC met to discuss ongoing reports of myocarditis in young people, particularly young men, after the 2nd dose of mRNA vaccines.

In light of these recent reports, the committee was charged with weighing potential harms and benefits associated with 2nd doses of mRNA vaccines.

Despite the importance and gravity of the topic, and the high level at which this discussion was taking place, the presentation given to the committee for the purpose of weighing those harms and benefits was fundamentally flawed.

While mi sleading statements and data can be found throughout the slidedeck, we will focus on two slides which are most relevant to the decision that was facing ACIP on June 23rd.

The first of these two slides, below, claims to evaluate the “benefits and risks after dose 2”, presenting what appears to be “COVID-19-Associated Hospitalizations Prevented” by dose 2, against “Cases of Myocarditis” which would be expected to be caused by dose 2.

Leave a Comment